Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Status:
Completed
Trial end date:
2016-08-19
Target enrollment:
Participant gender:
Summary
This study is designed to provide continued access to lapatinib as monotherapy or as part of
a combination regimen to cancer subjects who are currently participating in a phase I trial
that has met its study objectives.